Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

CNBX Pharmaceuticals (CNBX) Return on Equity (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Return on Equity for 13 consecutive years, with 0.12% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 6.0% year-over-year to 0.12%, compared with a TTM value of 0.12% through Nov 2025, down 6.0%, and an annual FY2025 reading of 0.13%, down 14.0% over the prior year.
  • Return on Equity was 0.12% for Q4 2025 at CNBX Pharmaceuticals, up from 0.11% in the prior quarter.
  • Across five years, Return on Equity topped out at 13.17% in Q4 2022 and bottomed at 49.72% in Q1 2022.
  • Average Return on Equity over 5 years is 2.47%, with a median of 0.15% recorded in 2025.
  • The sharpest move saw Return on Equity plummeted -4866bps in 2022, then skyrocketed 5061bps in 2023.
  • Year by year, Return on Equity stood at 2.9% in 2021, then skyrocketed by 554bps to 13.17% in 2022, then crashed by -97bps to 0.37% in 2023, then crashed by -51bps to 0.18% in 2024, then tumbled by -34bps to 0.12% in 2025.
  • Business Quant data shows Return on Equity for CNBX at 0.12% in Q4 2025, 0.11% in Q3 2025, and 0.08% in Q2 2025.